Join our daily newsletter At The Bell to receive exclusive market insights
- Orthocell (OCC) has been granted patents in China and Hong Kong for its novel CelGro collagen rope device to improve the surgical repair of ACL injuries
- The patents are now approved in the U.S., Australia, Japan, China and Hong Kong, offering the company additional intellectual property protection for its CelGro platform for soft tissue regeneration and repair applications, expiring in October 2035
- The company says they anticipate the release of its pre-clinical results in Q3 CY2021
- Company shares last traded at 49.5 cents on May 25
Orthocell (OCC) has been granted patents in China and Hong Kong for its novel CelGro collagen rope device.
The collagen rope device is used to improve the surgical repair of anterior cruciate ligament (ACL) injuries. The ACL is one of the major stabilising ligaments of the knee that connected the thigh bone to the shin bone and, once ruptured, it is incapable of healing.
The patents entitled “Collagen Construct and Method for Producing the Collagen Construct” are now approved in the United States, Australia, Japan, China and Hong Kong, offering the company additional intellectual property protection for its CelGro platform for soft tissue regeneration and repair applications. The patents will expire on October 12, 2035.
The company says approximately 15,000 ACL knee reconstructions are done annually in Australia, with up to a quarter of patients needing additional or revision surgery, resulting in a multi-billion-dollar market opportunity.
Reconstructing the ACL usually involves a hamstring graft, where part of the patient’s tendon is surgically removed and used to replace the ruptured ACL — a time consuming and potentially hazardous process, with a long recovery time.
Orthocell’s CelGro collagen rope made from braided collagen fibres is an alternative to harvesting the patient’s tendons. It reduces surgery time and mitigates the risk associated with removing a patient’s hamstring.
“There are currently no biological off-the-shelf solutions that mimic human ligament to enable the optimal repair of ACL injuries. The CelGro collagen rope addresses this problem,” said Orthocell Managing Director Paul Anderson.
“It is designed to augment ACL reconstruction without the need to harvest the patient’s hamstring or patella tendon and will disrupt the sports injury repair market by dramatically improving ACL surgery outcomes.”
The company says they anticipate the release of pre-clinical results in Q3 CY2021.
Company shares last traded at 49.5 cents on May 25.
